“Clinical review of subcutaneous semaglutide for obesity”. 《Journal of Clinical Pharmacy and Therapeutics》 47 (2): 184–193. February 2022. doi:10.1111/jcpt.13574. PMID34964141.
“Efficacy and safety of semaglutide for weight management: evidence from the STEP program”. 《Postgraduate Medicine》 134 (sup1): 5–17. January 2022. doi:10.1080/00325481.2022.2147326. PMID36691309.
“Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes”. 《Canadian Journal of Diabetes》 43 (2): 136–145. March 2019. doi:10.1016/j.jcjd.2018.05.008. PMID30195966.
“Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. 《The New England Journal of Medicine》 375 (19): 1834–1844. November 2016. doi:10.1056/NEJMoa1607141. PMID27633186.
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”. 《Journal of Medicinal Chemistry》 58 (18): 7370–80. September 2015. doi:10.1021/acs.jmedchem.5b00726. PMID26308095.
“The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates”. 《Diabetes》 63 (7): 2486–97. July 2014. doi:10.2337/db13-1087. PMID24608440.
“Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1–5, 2012. Berlin, Germany”. 《Diabetologia》 55 (S1): S7–537. October 2012. doi:10.1007/s00125-012-2688-9. PMID22918257.
“Once-Weekly Semaglutide in Adults with Overweight or Obesity”. 《The New England Journal of Medicine》 384 (11): 989–1002. March 2021. doi:10.1056/NEJMoa2032183. PMID33567185.
“Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. 《The New England Journal of Medicine》 385 (6): 503–515. August 2021. doi:10.1056/NEJMoa2107519. PMID34170647.
“Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis”. 《Diabetes & Metabolic Syndrome》 16 (6): 102539. June 2022. doi:10.1016/j.dsx.2022.102539. PMID35709586.
“Semaglutide and cancer: A systematic review and meta-analysis..”. 《Diabetes Metab Syndr》 17 (9): 102834. July 2023. doi:10.1016/j.dsx.2023.102834. PMID37531876.
“Wegovy EPAR”. 《European Medicines Agency》. 2021년 11월 11일. 2022년 7월 2일에 원본 문서에서 보존된 문서. 2022년 3월 11일에 확인함.
“Wegovy : Pending EC decision”. 《European Medicines Agency》. 2021년 11월 11일. 2021년 11월 13일에 원본 문서에서 보존된 문서. 2021년 11월 13일에 확인함. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
“Clinical review of subcutaneous semaglutide for obesity”. 《Journal of Clinical Pharmacy and Therapeutics》 47 (2): 184–193. February 2022. doi:10.1111/jcpt.13574. PMID34964141.
“Efficacy and safety of semaglutide for weight management: evidence from the STEP program”. 《Postgraduate Medicine》 134 (sup1): 5–17. January 2022. doi:10.1080/00325481.2022.2147326. PMID36691309.
“Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes”. 《Canadian Journal of Diabetes》 43 (2): 136–145. March 2019. doi:10.1016/j.jcjd.2018.05.008. PMID30195966.
“Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes”. 《The New England Journal of Medicine》 375 (19): 1834–1844. November 2016. doi:10.1056/NEJMoa1607141. PMID27633186.
“Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide”. 《Journal of Medicinal Chemistry》 58 (18): 7370–80. September 2015. doi:10.1021/acs.jmedchem.5b00726. PMID26308095.
“The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates”. 《Diabetes》 63 (7): 2486–97. July 2014. doi:10.2337/db13-1087. PMID24608440.
“Abstracts of the 48th EASD (European Association for the Study of Diabetes) Annual Meeting of the European Association for the Study of Diabetes. October 1–5, 2012. Berlin, Germany”. 《Diabetologia》 55 (S1): S7–537. October 2012. doi:10.1007/s00125-012-2688-9. PMID22918257.
“Once-Weekly Semaglutide in Adults with Overweight or Obesity”. 《The New England Journal of Medicine》 384 (11): 989–1002. March 2021. doi:10.1056/NEJMoa2032183. PMID33567185.
“Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes”. 《The New England Journal of Medicine》 385 (6): 503–515. August 2021. doi:10.1056/NEJMoa2107519. PMID34170647.
“Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: A meta-analysis”. 《Diabetes & Metabolic Syndrome》 16 (6): 102539. June 2022. doi:10.1016/j.dsx.2022.102539. PMID35709586.
“Semaglutide and cancer: A systematic review and meta-analysis..”. 《Diabetes Metab Syndr》 17 (9): 102834. July 2023. doi:10.1016/j.dsx.2023.102834. PMID37531876.
“Wegovy : Pending EC decision”. 《European Medicines Agency》. 2021년 11월 11일. 2021년 11월 13일에 원본 문서에서 보존된 문서. 2021년 11월 13일에 확인함. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.